Drugs: Real World Outcomes
نویسندگان
چکیده
It is our great pleasure to welcome you to Drugs: Real World Outcomes, the latest offering from Adis that targets research involving the use of real-world data. We all know that the gold standard in research is the randomized controlled clinical trial; however, we all also know that these trials by the nature of their design fail to inform clinicians on many fronts. While they provide vital confirmation of efficacy and safety, they exclude many relevant patient groups, such as the elderly, children and those with comorbidities, and they are conducted in ideal settings, with an expectation of high adherence rates. Clinicians need to know how their patients will respond to a drug in real life— and the potential impact of factors such as race, age, sex, comorbidities, performance status and other medications. Drugs: Real World Outcomes aims to provide a vehicle for dissemination and a forum for discussion of information about how drugs perform in daily clinical practice. We will include both original research and definitive reviews on the use of real-world data to help you evaluate health outcomes and make informed healthcare decisions on drugs, devices and other interventions. Adis has been publishing high quality journals for over 40 years, with experience in the areas of drug treatment, drug safety, pharmacokinetics, pharmacoeconomics and molecular diagnostics amongst others, and has a current portfolio of more than 30 journals. Drugs was first published in 1971 and has developed a reputation as the go-to source of information on drug treatment and drug evaluation. Over the years, the family of Drugs has grown to include Drug Safety, Drugs & Aging, BioDrugs, Pediatric Drugs and Drugs in R&D. With Drugs: Real World Outcomes, we now apply our knowledge and experience to bring you investigations on drug utilization, patterns of prescribing, pharmacovigilance, treatment guideline adherence, benefit-risk assessments, comparative effectiveness and economic analyses. The journal will be published online only and will be entirely open access. Now that the Adis portfolio of journals has been successfully integrated into the production systems and online platforms provided by Springer, as an Adis Open journal we can offer authors
منابع مشابه
Basing approval of drugs for type 2 diabetes on real world outcomes.
Naci and colleagues rightly point out that although drugs are often approved on the basis of glucose lowering efficacy, we really need agents that reduce important outcomes such as symptomatic microvascular disease and cardiovascular events. The authors suggest that real world evidence of clinical effectiveness should be required from the drug industry, using routine healthcare data to monitor ...
متن کاملGaps in the evaluation and monitoring of new pharmaceuticals: proposal for a different approach.
© 2003 Canadian Medical Association or its licensors The marked increase in spending on drugs 1 has led payers such as provincial governments to restrict funding for many drugs to specific clinical indications that are thought to be cost-effective. Some have argued that this unreasonably deprives patients of access to beneficial drugs. In this article we argue for a new approach to drug evaluat...
متن کاملThe First Eastern Mediterranean Region/Arab Countries Meeting of Pharmacovigilance
With many drugs coming to market and post-marketing surveillance limited to industry, there is a need for an integrated common approach to pharmacovigilance (PV) in the Eastern Mediterranean Region (EMR)/Arab region. The first meeting of the EMR/Arab countries for PV involved ten of the 22 states and revealed how these countries are learning from and working with each other in order to achieve ...
متن کاملAssociation Between Statin Medications and COPD-Specific Outcomes: A Real-World Observational Study
BACKGROUND Disease-modifying drugs are not yet available for the management of chronic obstructive pulmonary disease (COPD). HMG-CoA reductase inhibitors (statins) have anti-inflammatory properties and are therefore being considered for use in the management of COPD. OBJECTIVE Our objective was to examine the association between statin use and COPD-specific outcomes in a real-world setting. ...
متن کاملNon-valvular atrial fibrillation: impact of apixaban on patient outcomes
Atrial fibrillation is the most common arrhythmia worldwide, and carries a significantly increased risk of thromboembolic stroke. Initially, vitamin K antagonists were used as stroke prophylaxis; but more recently, a group of drugs known as novel oral anticoagulants have been developed. Apixaban belongs to this group of drugs, and is a factor Xa inhibitor that has emerged as a popular pharmacol...
متن کامل